Roche: Oddo confirms buy rating.
(CercleFinance.com) - This morning Roche announced a number results of very positive results from clinical trials.
Following this announcement, Oddo confirmed its buy rating on the stock, with a target price of 284 Swiss francs.
The group first announced that the results of the IMpower150 study are positive. Of course, it will be necessary to wait for precise figures to assess the potential of this combination in first-line lung cancer treatment in combination (a market worth over 15 billion dollars in our opinion), Oddo says.
We estimate that Tecentriq's potential in this indication at over 3.6 billion Swiss francs when sales peak, a figure that we adjust for a 60% probability of success.
The group also announced a phase 3 HAVEN 3 study which overall was positive for patients suffering from hemophilia A. HAVEN 3 evaluated emicizumab (Hemlibra) in patients suffering from hemophilia A without inhibitors and showed a statistically significant reduction in the number of bleeds in patients with hemophilia A compared to on-demand treatment.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
Following this announcement, Oddo confirmed its buy rating on the stock, with a target price of 284 Swiss francs.
The group first announced that the results of the IMpower150 study are positive. Of course, it will be necessary to wait for precise figures to assess the potential of this combination in first-line lung cancer treatment in combination (a market worth over 15 billion dollars in our opinion), Oddo says.
We estimate that Tecentriq's potential in this indication at over 3.6 billion Swiss francs when sales peak, a figure that we adjust for a 60% probability of success.
The group also announced a phase 3 HAVEN 3 study which overall was positive for patients suffering from hemophilia A. HAVEN 3 evaluated emicizumab (Hemlibra) in patients suffering from hemophilia A without inhibitors and showed a statistically significant reduction in the number of bleeds in patients with hemophilia A compared to on-demand treatment.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.